DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Koate-DVI (Antihemophilic Factor) - Published Studies


Koate-DVI Related Published Studies

Well-designed clinical trials related to Koate-DVI (Antihemophilic Factor)

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. [2000.06]

Well-designed clinical trials possibly related to Koate-DVI (Antihemophilic Factor)

Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. [2013]

Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial. [2011.10]

In vivo biological effects of foam sclerotherapy. [2011.08]

International comparative field study of N8 evaluating factor VIII assay performance. [2011.07]

Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. [2011.05]

Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. [2011.04]

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). [2011.04]

Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). [2011.02.22]

Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study. [2010.11]

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. [2010.06.20]

Effect of two oral doses of 17beta-estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double-blind placebo-controlled study. [2010.04]

Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue. [2010.01]

Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. [2009.08]

Role of fibrinogen-, factor VIII- and XIII-mediated clot propagation in gelatin haemodilution. [2009.07]

6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. [2009.05]

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. [2009.03.10]

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. [2008.12.01]

Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. [2008.11.10]

Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. [2008.11]

Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. [2008.09]

Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. [2008.07]

Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. [2008.06]

Effect of oral melatonin on the procoagulant response to acute psychosocial stress in healthy men: a randomized placebo-controlled study. [2008.05]

Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection. [2008.04]

p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. [2008.04]

Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. [2008.03]

Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. [2008.02]

A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. [2008.02]

Understanding tubulin/microtubule-taxane interactions: a quantitative structure-activity relationship study. [2008.01]

Prevention of haemophilic synovitis: prophylaxis. [2007.11]

Analysing two dinucleotide repeats of FVIII gene in Iranian population. [2007.11]

Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. [2007.09.01]

A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. [2007.09]

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. [2007.08.09]

Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven(R) (Hydroxyethyl Starch 130/0.4) or Hetastarch. [2007.06]

Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. [2007.06]

Exhaustive exercise with high eccentric components induces prothrombotic and hypofibrinolytic responses in boys. [2007.03]

A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. [2007.02]

A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. [2007.02]

Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A. [2007.01]

Assessing Efficacy and Therapeutic Claims in Emerging Indications for Recombinant Factor VIIa: Regulatory Perspectives. [2006.01]

Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. [2006]

Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. [2005.10]

Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. [2005.04]

B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. [2005.03]

Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. [2005.01.08]

Comparing hand-held computers and paper diaries for haemophilia home therapy: a randomized trial. [2004.11]

Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion. [2004.11]

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. [2004.09]

Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial. [2004.04]

Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial. [2004.03]

Effects of oxypolygelatin and dextran 70 on hemostatic variables in dogs. [2003.10]

The effects of intermittent prebypass heparin dosing in patients undergoing coronary artery bypass grafting. [2003.09]

Cryoprecipitate for the correction of coagulopathy associated with liver disease. [2003.08]

Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. [2003.08]

Prospective controlled studies on prophylaxis: an Italian approach. [2003.05]

Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. [2003.05]

Comparison of RBCs and FFP with whole blood during liver transplant surgery. [2003.03]

The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: a preliminary survey of hemostatic markers. [2003.02]

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. [2003.01]

Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. [2002.12]

The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. [2002.10]

Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. [2002.05]

Desmopressin usage in elective cardiac surgery. [2001.12]

Effects of hormone replacement on hemostasis in spontaneous menopause. [2001.06]

Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. [2000.05]

Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. [2000.03]

Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. [1999.12]

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. [1999.08.17]

Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate. [1999.07]

Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis. [1999.04]

Procoagulant activity and cytokine expression in whole blood cultures from patients with atherosclerosis supplemented with omega-3 fatty acids. [1999.04]

Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis. [1999.01]

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. [1998.11]

Application of cryoprecipitate as a hematostatic glue. [1998.10]

Type 2N von Willebrand disease: rapid genetic diagnosis of G2811A (R854Q), C2696T (R816W), T2701A (H817Q) and G2823T (C858F)--detection of a novel candidate type 2N mutation: C2810T (R854W). [1998.07]

Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. [1998.06]

Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. [1998]

Partial blockade of nitric oxide synthase blunts the exercise-induced increase of von Willebrand factor antigen and of factor VIII in man. [1997.10]

Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A. [1997.04]

Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. [1997.02]

Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. [1996.12]

The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C. [1996.10]

Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. [1996.09]

Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. [1996.08.15]

Effects of supplemental dietary arginine, canola oil, and trace elements on cellular immune function in critically injured patients. [1996.07]

A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern Ireland. [1995.12]

Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. [1995.10]

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. [1995.10]

Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study. [1995.10]

The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. [1995.03]

Bovine factor VIII derivative in the treatment of non-proliferative diabetic retinopathy. [1995]

Study of the interaction of dextran and enoxaparin on haemostasis in humans. [1994.11]

A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. [1994.02]

A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. [1993.11.15]

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. [1993.09.18]

Estrogen and progesterone receptors in human decidua after RU486 treatment. [1993.07]

Fibrinolytic and hemostatic parameter response after resistance exercise. [1993.05]

A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. [1993.02.01]

Anaesthesia affects plasma concentrations of vasopressin, von Willebrand factor and coagulation factor VIII in cardiac surgical patients. [1993.02]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017